A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Hematologic Neoplasms
Both
Hematologic Neoplasms
Trial Information
A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Inclusion Criteria:
- >18 years old
- Karnofsky performance status > 60
- confirmed hematological malignancy
- refractory to available therapy or for which no therapy is available
- adequate hepatic, renal and hematological function
Exclusion Criteria:
- CNS malignancy
- at risk for prolonged QT interval
- significant GI/liver disease
- other serious concurrent illness or medical condition
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
adverse events and other safety assessments
Outcome Time Frame:
continuous
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
B1311002
NCT ID:
NCT00595686
Start Date:
January 2008
Completion Date:
May 2010
Related Keywords:
- Hematologic Neoplasms
- Hematologic Malignancies Hsp90 Hematologic Malignancy
- Neoplasms
- Hematologic Neoplasms
Name | Location |
|---|---|
| Pfizer Investigational Site | Atlanta, Georgia 30342 |
| Pfizer Investigational Site | Asheville, North Carolina 28801 |
| Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |
| Pfizer Investigational Site | Bristol, Tennessee 37620 |
